MIR 1246 and MIR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer

Tatsuya Machida, Takaaki Tomofuji, Takayuki Maruyama, Toshiki Yoneda, Daisuke Ekuni, Tetsuji Azuma, Hisataka Miyai, Hirofumi Mizuno, Hironari Katou, Koichiro Tsutsumi, Daisuke Uchida, Akinobu Takaki, Hiroyuki Okada, Manabu Morita

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Pancreatobiliary tract cancer is a highly fatal cancer. Detection of pancreatobiliary tract cancer is difficult because it lacks typical clinical symptoms and because of its anatomical location. Biomarker discovery is therefore important to detect pancreatobiliary tract cancer in its early stage. A study demonstrated that expression levels of MIR-1246, MIR-3976, MIR-4306, and MIR-4644 in serum exosomes were higher in pancreatic cancer patients than these levels in healthy control participants. Supposing that microRNA (miRNA) expression profiles in saliva are similar to those in serum, four miRNAs (miR-1246, MIR-3976, MIR-4306, and MIR-4644) in salivary exosomes may also be useful for detection of pancreatobiliary tract cancer. In this study, it was examined whether these miRNAs could be used as biomarkers for pancreatobiliary tract cancer. Twelve pancreatobiliary tract cancer patients and 13 healthy control participants were analyzed as a cancer and a control group, respectively. Unstimulated whole saliva was collected, salivary exosomes were isolated, and total RNA was extracted. Using quantitative real-time PCR (RT-qPCR), the relative expression ratios of MIR-1246 and MIR-4644 were significantly higher in the cancer group than these ratios in the control group. Receiver operating characteristic (ROC) curves were constructed to analyze the discrimination power of these miRNAs. For MIR-1246, the results yielded an area under the curve (AUC) of 0.814 (P=0.008). For MIR-4644, the results yielded an AUC of 0.763 (P=0.026). For the combination of MIR-1246 and MIR-4644, the results yielded an increased AUC of 0.833 (P=0.005). This pilot study suggests that MIR-1246 and MIR-4644 in salivary exosomes could be candidate biomarkers for pancreatobiliary tract cancer.

Original languageEnglish
Pages (from-to)2375-2381
Number of pages7
JournalOncology Reports
Volume36
Issue number4
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Exosomes
Biomarkers
Neoplasms
MicroRNAs
Area Under Curve
Saliva
Healthy Volunteers
Control Groups
Serum
Pancreatic Neoplasms
ROC Curve
Real-Time Polymerase Chain Reaction
RNA

Keywords

  • Biomarkers
  • Case-control studies
  • Micrornas
  • MIR-1246
  • MIR-4644
  • Neoplasms
  • Pancreatobiliary cancer
  • Saliva
  • Salivary exosomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MIR 1246 and MIR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. / Machida, Tatsuya; Tomofuji, Takaaki; Maruyama, Takayuki; Yoneda, Toshiki; Ekuni, Daisuke; Azuma, Tetsuji; Miyai, Hisataka; Mizuno, Hirofumi; Katou, Hironari; Tsutsumi, Koichiro; Uchida, Daisuke; Takaki, Akinobu; Okada, Hiroyuki; Morita, Manabu.

In: Oncology Reports, Vol. 36, No. 4, 01.10.2016, p. 2375-2381.

Research output: Contribution to journalArticle

@article{7ade4c08519344e19d302f2efcb5c599,
title = "MIR 1246 and MIR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer",
abstract = "Pancreatobiliary tract cancer is a highly fatal cancer. Detection of pancreatobiliary tract cancer is difficult because it lacks typical clinical symptoms and because of its anatomical location. Biomarker discovery is therefore important to detect pancreatobiliary tract cancer in its early stage. A study demonstrated that expression levels of MIR-1246, MIR-3976, MIR-4306, and MIR-4644 in serum exosomes were higher in pancreatic cancer patients than these levels in healthy control participants. Supposing that microRNA (miRNA) expression profiles in saliva are similar to those in serum, four miRNAs (miR-1246, MIR-3976, MIR-4306, and MIR-4644) in salivary exosomes may also be useful for detection of pancreatobiliary tract cancer. In this study, it was examined whether these miRNAs could be used as biomarkers for pancreatobiliary tract cancer. Twelve pancreatobiliary tract cancer patients and 13 healthy control participants were analyzed as a cancer and a control group, respectively. Unstimulated whole saliva was collected, salivary exosomes were isolated, and total RNA was extracted. Using quantitative real-time PCR (RT-qPCR), the relative expression ratios of MIR-1246 and MIR-4644 were significantly higher in the cancer group than these ratios in the control group. Receiver operating characteristic (ROC) curves were constructed to analyze the discrimination power of these miRNAs. For MIR-1246, the results yielded an area under the curve (AUC) of 0.814 (P=0.008). For MIR-4644, the results yielded an AUC of 0.763 (P=0.026). For the combination of MIR-1246 and MIR-4644, the results yielded an increased AUC of 0.833 (P=0.005). This pilot study suggests that MIR-1246 and MIR-4644 in salivary exosomes could be candidate biomarkers for pancreatobiliary tract cancer.",
keywords = "Biomarkers, Case-control studies, Micrornas, MIR-1246, MIR-4644, Neoplasms, Pancreatobiliary cancer, Saliva, Salivary exosomes",
author = "Tatsuya Machida and Takaaki Tomofuji and Takayuki Maruyama and Toshiki Yoneda and Daisuke Ekuni and Tetsuji Azuma and Hisataka Miyai and Hirofumi Mizuno and Hironari Katou and Koichiro Tsutsumi and Daisuke Uchida and Akinobu Takaki and Hiroyuki Okada and Manabu Morita",
year = "2016",
month = "10",
day = "1",
doi = "10.3892/or.2016.5021",
language = "English",
volume = "36",
pages = "2375--2381",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - MIR 1246 and MIR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer

AU - Machida, Tatsuya

AU - Tomofuji, Takaaki

AU - Maruyama, Takayuki

AU - Yoneda, Toshiki

AU - Ekuni, Daisuke

AU - Azuma, Tetsuji

AU - Miyai, Hisataka

AU - Mizuno, Hirofumi

AU - Katou, Hironari

AU - Tsutsumi, Koichiro

AU - Uchida, Daisuke

AU - Takaki, Akinobu

AU - Okada, Hiroyuki

AU - Morita, Manabu

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Pancreatobiliary tract cancer is a highly fatal cancer. Detection of pancreatobiliary tract cancer is difficult because it lacks typical clinical symptoms and because of its anatomical location. Biomarker discovery is therefore important to detect pancreatobiliary tract cancer in its early stage. A study demonstrated that expression levels of MIR-1246, MIR-3976, MIR-4306, and MIR-4644 in serum exosomes were higher in pancreatic cancer patients than these levels in healthy control participants. Supposing that microRNA (miRNA) expression profiles in saliva are similar to those in serum, four miRNAs (miR-1246, MIR-3976, MIR-4306, and MIR-4644) in salivary exosomes may also be useful for detection of pancreatobiliary tract cancer. In this study, it was examined whether these miRNAs could be used as biomarkers for pancreatobiliary tract cancer. Twelve pancreatobiliary tract cancer patients and 13 healthy control participants were analyzed as a cancer and a control group, respectively. Unstimulated whole saliva was collected, salivary exosomes were isolated, and total RNA was extracted. Using quantitative real-time PCR (RT-qPCR), the relative expression ratios of MIR-1246 and MIR-4644 were significantly higher in the cancer group than these ratios in the control group. Receiver operating characteristic (ROC) curves were constructed to analyze the discrimination power of these miRNAs. For MIR-1246, the results yielded an area under the curve (AUC) of 0.814 (P=0.008). For MIR-4644, the results yielded an AUC of 0.763 (P=0.026). For the combination of MIR-1246 and MIR-4644, the results yielded an increased AUC of 0.833 (P=0.005). This pilot study suggests that MIR-1246 and MIR-4644 in salivary exosomes could be candidate biomarkers for pancreatobiliary tract cancer.

AB - Pancreatobiliary tract cancer is a highly fatal cancer. Detection of pancreatobiliary tract cancer is difficult because it lacks typical clinical symptoms and because of its anatomical location. Biomarker discovery is therefore important to detect pancreatobiliary tract cancer in its early stage. A study demonstrated that expression levels of MIR-1246, MIR-3976, MIR-4306, and MIR-4644 in serum exosomes were higher in pancreatic cancer patients than these levels in healthy control participants. Supposing that microRNA (miRNA) expression profiles in saliva are similar to those in serum, four miRNAs (miR-1246, MIR-3976, MIR-4306, and MIR-4644) in salivary exosomes may also be useful for detection of pancreatobiliary tract cancer. In this study, it was examined whether these miRNAs could be used as biomarkers for pancreatobiliary tract cancer. Twelve pancreatobiliary tract cancer patients and 13 healthy control participants were analyzed as a cancer and a control group, respectively. Unstimulated whole saliva was collected, salivary exosomes were isolated, and total RNA was extracted. Using quantitative real-time PCR (RT-qPCR), the relative expression ratios of MIR-1246 and MIR-4644 were significantly higher in the cancer group than these ratios in the control group. Receiver operating characteristic (ROC) curves were constructed to analyze the discrimination power of these miRNAs. For MIR-1246, the results yielded an area under the curve (AUC) of 0.814 (P=0.008). For MIR-4644, the results yielded an AUC of 0.763 (P=0.026). For the combination of MIR-1246 and MIR-4644, the results yielded an increased AUC of 0.833 (P=0.005). This pilot study suggests that MIR-1246 and MIR-4644 in salivary exosomes could be candidate biomarkers for pancreatobiliary tract cancer.

KW - Biomarkers

KW - Case-control studies

KW - Micrornas

KW - MIR-1246

KW - MIR-4644

KW - Neoplasms

KW - Pancreatobiliary cancer

KW - Saliva

KW - Salivary exosomes

UR - http://www.scopus.com/inward/record.url?scp=84985010787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985010787&partnerID=8YFLogxK

U2 - 10.3892/or.2016.5021

DO - 10.3892/or.2016.5021

M3 - Article

C2 - 27573701

AN - SCOPUS:84985010787

VL - 36

SP - 2375

EP - 2381

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -